Bromantane

What Is Bromantane?

Bromantane (brand name Ladasten) is a synthetic adamantane-derivative described in Russian pharmacology as an “actoprotector” — a mild stimulant/anxiolytic intended to improve performance under stress without the crash of a classical stimulant. It is used for asthenia (fatigue-like states) and low energy. It is approved as a medicine in Russia but is not approved as a drug or dietary supplement in the US or EU, and most of its clinical literature is Russian-language, which limits independent scrutiny. Treat the human evidence as real but narrow and hard to verify at source.

Evidence

The most relevant human study is a comparative, placebo-controlled clinical trial of Ladasten (bromantane) in neurasthenia/asthenic disorders, which reported combined psychostimulant and anxiolytic effects and better outcomes than placebo ^{1Reference 1Neznamov et al. · 2009RCTLadasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (comparative clinical study with placebo) — randomised/placebo-controlledView study →}. Mechanistically, bromantane is grouped with actoprotectors in a pharmacology review that describes this class’s use for improving mental and physical performance; preclinical work associates bromantane with up-regulation of dopamine-synthesis machinery (e.g. tyrosine hydroxylase) rather than simple reuptake blockade ^{2Reference 2Oliynyk et al. · 2012ReviewThe pharmacology of actoprotectors: practical application for improvement of mental and physical performance — reviewView study →}. The frequently quoted large “728-patient, ~90% improvement” figures come from Russian-language reports I could not independently verify in this quick pass, so they should be treated as unconfirmed. Overall: some genuine controlled human data exist, but the corpus is small, largely single-region, and not well represented in mainstream English-language databases.

Dosage & Safety

Russian asthenia studies have typically used roughly 50–100 mg/day for about 28 days ^{1Reference 1Neznamov et al. · 2009RCTLadasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (comparative clinical study with placebo) — randomised/placebo-controlledView study →}; this describes what was studied and is not a personal recommendation. Bromantane is a prescription-status medicine in Russia and is not an approved supplement or medicine in the US/EU; anything sold elsewhere is effectively a research chemical. It is also a WADA-prohibited substance in sport (it was involved in doping cases), which is a concrete, verifiable caution for athletes. Long-term safety, drug interactions and use in pregnancy are not well characterised in accessible literature. This entry is informational only. Toxicity has not been formally characterised here.

References

1. Neznamov, G. G., Siuniakov, S. A., et al. (2009). Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (comparative clinical study with placebo) — randomised/placebo-controlled. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. https://pubmed.ncbi.nlm.nih.gov/19491814/
2. Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: practical application for improvement of mental and physical performance — review. Biomolecules & Therapeutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC3762282/